Recce Pharmaceuticals

Recce Pharmaceuticals CROIC

The Cash Return on Invested Capital (CROIC) of Recce Pharmaceuticals (RCE.AX) as of Oct 29, 2026 is 158.46 %. In the previous year, Cash Return on Invested Capital (CROIC) was -265.26 % — a change of -159.74% (higher).

CROIC

158.46 %

YoY

-159.74%

Last updated:

Cash Return on Invested Capital (CROIC) of Recce Pharmaceuticals is 2026 158.46 % . Cash Return on Invested Capital (CROIC) of Recce Pharmaceuticals was 2025 -265.26 % . It decreases by -159.74% higher compared to the previous year.

The Recce Pharmaceuticals CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
-814.35 AUD
Jan 1, 2020
-159.17 AUD
Jan 1, 2021
-38.45 AUD
Jan 1, 2022
-89.29 AUD
Jan 1, 2023
544.26 AUD
Jan 1, 2024
150.94 AUD
Jan 1, 2025
-265.26 AUD
Jan 1, 2026
158.46 AUD
The Recce Pharmaceuticals CROIC history
YEARCROICYoY
158.46 %-159.74%
-265.26 %-275.74%
150.94 %-72.27%
544.26 %-709.53%
-89.29 %+132.24%
-38.45 %-75.85%
-159.17 %-80.45%
-814.35 %+197.49%
-273.74 %-8.95%
-300.63 %+527.93%
-47.88 %+581.07%
-7.03 %-116.58%
42.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Cash Return on Invested Capital (CROIC) of Recce Pharmaceuticals is 158.46 % in 2026.

Cash Return on Invested Capital (CROIC) of Recce Pharmaceuticals changed from -265.26 % to 158.46 %, representing a -159.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Recce Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Recce Pharmaceuticals